1. Home
  2. |Insights
  3. |Emerging Issues in Sanctions, AML and Everything in Between in the Time of COVID-19: 2020 AML & Sanctions Risk Considerations for Digital Assets Companies

Emerging Issues in Sanctions, AML and Everything in Between in the Time of COVID-19: 2020 AML & Sanctions Risk Considerations for Digital Assets Companies

Webinar | 05.19.20, 5:30 AM EDT - 6:30 AM EDT

Register

For Crowell & Moring LLP’s next event in our series, Emerging Issues in Sanctions, AML, and Everything in Between in the Time of COVID-19, our Global Head of Blockchain & Digital Assets, Michelle Gitlitz, will moderate a discussion on the AML & Sanctions risks that digital assets companies are currently grappling with.


Join us from the comfort of your home office (couch, bed, bathroom—we see you working parents), to hear our AML & Sanctions pros discuss the following pressing topics:


How Do AML and Sanctions Laws Apply to Digital Assets? What are the Key Regulatory Risks?

  • What kinds of digital assets businesses are subject to AML regulation?
  • What kind of AML obligations do regulated entities have?
  • How do sanctions apply to digital assets transactions, assets, and wallets?
  • What sanctions obligations do digital assets businesses have?

Potential Areas for AML and Sanctions Enforcement for Digital Assets in 2020

  • Unregistered money transmitter
  • Inadequate AML programs and failure to file SARs
  • The Funds Transfer and Travel Rules
  • OFAC’s interest in digital assets companies 
  • Expert advice on virtual currency to sanctioned parties 

The potential Impact of COVID-19

  • Is there an increase in the use of cryptocurrency by sanctioned persons, money launderers and fraudsters during COVID-19?

For more information, please visit these areas: Corporate and Transactional, International Trade, White Collar and Regulatory Enforcement, Privacy and Cybersecurity

Contact

Participants

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

View All Insights